Osteogenic Protein-1 and Insulin-Like Growth Factor I Synergistically Stimulate Rat Osteoblastic Cell Differentiation and Proliferation

Yeh, Lee Chuan C

doi:10.1210/en.138.10.4181

Cited by 61 publications

(76 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with the control group without growth factor, addition of OP-1 stimulated an additional 10% increase in bone formation, which agrees with our previous experiment, in which OP-1 was pipetted at 330 ng/ml daily (data not shown), and studies from other laboratories demonstrating OP-1 stimulates the differentiation of osteoprogenitor cells [2,28,29,[31][32][33]. Differentiation of the osteoprogenitor cells without addition of growth factors was synchronous with an increase of OC between Days 15 and 20 followed by a slower increase later on (slope of 0.44) (Fig.…”

Section: Discussionsupporting

confidence: 91%

Controlled Release of Growth Factors on Allograft Bone in vitro

Huang

Ryu

Ren

et al. 2008

Clin Orthop Relat Res

View full text Add to dashboard Cite

Allografts are important alternatives to autografts for treating defects after major bone loss. Bone growth factors have both local autocrine and paracrine effects and regulate the growth, proliferation, and differentiation of osteoprogenitor cells. To study the effects of prolonged, continuous, local delivery of growth factors on bone growth, we developed a new microelectromechanical system (MEMS) drug delivery device. Bone marrow cells from mice were seeded on mouse allograft discs and cultured in osteogenic media with osteogenic protein 1 (OP-1) and/or basic fibroblast growth factor (FGF-2) delivered from MEMS devices for 6 weeks. We monitored bone formation by changes of bone volume using micro-CT scanning and release of osteocalcin using ELISA. The data suggest the MEMS devices delivered constant concentrations of OP-1 and FGF-2 to the media. Bone marrow cells grew on the allografts and increased bone volume. Addition of OP-1 increased bone formation whereas FGF-2 decreased bone formation. Local delivery of growth factors over a prolonged period modulated the differentiation of osteoprogenitor cells on allograft bone.

show abstract

Section: Discussionsupporting

confidence: 91%

Controlled Release of Growth Factors on Allograft Bone in vitro

Huang

Ryu

Ren

et al. 2008

Clin Orthop Relat Res

View full text Add to dashboard Cite

show abstract

“…287,288 Multiple researchers have also observed a synergistic effect (i.e., enhance bone formation) from local sequential administration of multiple growth factors on osteoprogenitor and osteoblast cells in vitro and in vivo. [289][290][291][292] Despite this, many synthetic bone scaffolds rely on the delivery of single factors, which may partially explain the limited clinical utility of many current approaches. 262 Therefore, researchers have been investigating techniques to encapsulate and release multiple bioactive molecules in a highly controlled spatial and temporal manner.…”

Section: Delivery Of Multiple Bioactive Moleculesmentioning

confidence: 99%

Bone tissue engineering: A review in bone biomimetics and drug delivery strategies

Porter

Ruckh

Popat

2009

Biotechnology Progress

685

499

View full text Add to dashboard Cite

Critical‐sized defects in bone, whether induced by primary tumor resection, trauma, or selective surgery have in many cases presented insurmountable challenges to the current gold standard treatment for bone repair. The primary purpose of a tissue‐engineered scaffold is to use engineering principles to incite and promote the natural healing process of bone which does not occur in critical‐sized defects. A synthetic bone scaffold must be biocompatible, biodegradable to allow native tissue integration, and mimic the multidimensional hierarchical structure of native bone. In addition to being physically and chemically biomimetic, an ideal scaffold is capable of eluting bioactive molecules (e.g., BMPs, TGF‐βs, etc., to accelerate extracellular matrix production and tissue integration) or drugs (e.g., antibiotics, cisplatin, etc., to prevent undesired biological response such as sepsis or cancer recurrence) in a temporally and spatially controlled manner. Various biomaterials including ceramics, metals, polymers, and composites have been investigated for their potential as bone scaffold materials. However, due to their tunable physiochemical properties, biocompatibility, and controllable biodegradability, polymers have emerged as the principal material in bone tissue engineering. This article briefly reviews the physiological and anatomical characteristics of native bone, describes key technologies in mimicking the physical and chemical environment of bone using synthetic materials, and provides an overview of local drug delivery as it pertains to bone tissue engineering is included. © 2009 American Institute of Chemical Engineers Biotechnol. Prog., 2009

show abstract

“…BMP-7 stimulates proliferation [51] and differentiation [52] of pluripotent mesenchymal cell lines as well as angiogenesis through osteoblast-derived vascular endothelial growth factor [14]. Vascular supply at the fracture site has been considered for years the main cause of atrophic nonunions [1,7,48].…”

Section: Introductionmentioning

confidence: 99%

The Synergistic Effect of Autograft and BMP-7 in the Treatment of Atrophic Nonunions

Giannoudis

Kanakaris

Dimitriou

et al. 2009

Clin Orthop Relat Res

118

View full text Add to dashboard Cite

Combining autologous bone graft and recombinant human bone morphogenetic protein-7 (BMP-7) to treat long-bone fracture aseptic atrophic nonunions theoretically could promote bone healing at higher rates than each of these grafting agents separately. We retrospectively reviewed prospectively collected data on patient general characteristics, clinical outcomes, and complications over 3 years to determine the healing rates and the incidence of complications and adverse events of this ''graft expansion rationale.'' There were 45 patients (32 male) with a median age of 43 years (range, 19-76 years). Minimum followup was 12 months (mean, 24.5 months; range, 12-65 months). There were seven humeral, 19 femoral, and 19 tibial nonunions. The median number of prior operations was two (range, 1-7). All fractures united. Clinical and radiographic union occurred within a median of 5 months (range, 3-14 months) and 6 months (range, 4-16 months), respectively. Thirty-nine (87%) patients returned to their preinjury occupation at a mean of 4.2 months (range, 3-6 months). The median visual analog scale pain score was 0.9 (range, 0-2.8; maximum 10), and the median functional score was 86 (range, 67-95; maximum 100) at the final followup. BMP-7 as a bone-stimulating agent combined with conventional autograft resulted in a nonunion healing rate of 100% in these 45 patients.

show abstract

Osteogenic Protein-1 and Insulin-Like Growth Factor I Synergistically Stimulate Rat Osteoblastic Cell Differentiation and Proliferation

Cited by 61 publications

References 0 publications

Controlled Release of Growth Factors on Allograft Bone in vitro

Controlled Release of Growth Factors on Allograft Bone in vitro

Bone tissue engineering: A review in bone biomimetics and drug delivery strategies

The Synergistic Effect of Autograft and BMP-7 in the Treatment of Atrophic Nonunions

Contact Info

Product

Resources

About